Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 3/20 | 0.49 |
| ▸ | IDO1 | P14902 | 4/20 | 0.49 |
| ▸ | TDO2 | P48775 | 4/20 | 0.49 |
| ▸ | EIF4A3 | P38919 | 2/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29813037 | 0.84 | ULK1 (0.45) | RHEBIDO1TDO2ARNPC1 | |
| SCHEMBL23148123 | 0.84 | ULK1 (0.45) | RHEBIDO1TDO2ARNPC1 | |
| SCHEMBL23147975 | 0.83 | IDO1 (0.47) | RHEBIDO1TDO2EIF4A3GRIN1 | |
| SCHEMBL28461413 | 0.81 | GRIN1 (0.64) | RHEBEIF4A3GRIN1KDM4ELMNA | |
| SCHEMBL6448130 | 0.81 | RHEB (0.52) | RHEBIDO1TDO2EIF4A3GRIN1 | |
| SCHEMBL23147766 | 0.80 | EIF4A3 (0.64) | RHEBIDO1TDO2EIF4A3PIN1 | |
| SCHEMBL1761165 | 0.78 | NPC1 (0.61) | RHEBIDO1TDO2EIF4A3PIN1 | |
| SCHEMBL29784177 | 0.78 | NPC1 (0.61) | RHEBIDO1TDO2EIF4A3PIN1 | |
| SCHEMBL30310417 | 0.76 | KDM4E (0.53) | RHEBGRIN1KDM4EALDH1A1LMNA | |
| SCHEMBL1144458 | 0.76 | KDM4E (0.53) | RHEBGRIN1KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230040909-A1 | INDOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230040909-A1 | INDOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2023-02-09 | — | — | US | disclosed |
| EP-4034103-A1 | INDOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | The Global Alliance for TB Drug Development, Inc. (US) | 2022-08-03 | — | — | EP | disclosed |
| CN-114746088-A | Indole carboxamide compounds and their use for the treatment of mycobacterial infections | 结核病药物开发全球联盟公司 | 2022-07-12 | — | — | CN | disclosed |
| WO-2021062319-A1 | INDOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
| WO-2021062319-A1 | INDOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2021-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230040909-A1 | INDOLE CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR THE TREATMENT OF MYCOBACTERIAL INFECTIONS | IDO1, IDO2, INMT | RHEB 2161/4885IDO1 1/4885TDO2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.